Ajanta Pharma Limited and Dr. Reddy’s Laboratories Ltd announced the final approval from US FDA and launch of omeprazole and sodium bicarbonate capsules in the US market. It is a bioequivalent prescription generic version of Zegerid which is a registered trademark of Santarus, Inc, a wholly owned subsidiary of Salix Pharmaceuticals, Inc.

Both the companies launched the product in 2 strengths 20mg/1100mg & 40mg/1100mg capsules. Dr. Reddy’s capsules are available in bottle count size of 30.

Ajanta Pharma launched omeprazole and sodium bicarbonate capsules in the US market through its wholly owned subsidiary Ajanta Pharma USA Inc. Omeprazole and sodium bicarbonate capsules is part of an ever-growing portfolio of products that Ajanta has developed for the US market. In total, Ajanta has 26 Abbreviated New Drug Application (ANDA) of which it has final approvals for 11 ANDAs; tentative approvals for 1 ANDA; and 14 ANDAs are under review with US FDA.

The Zegerid brand and generic had US sales of approximately $306.7 million MAT for the most recent twelve months ending in May 2016 according to IMS Health.